Press Release

ALL

2022

2021

2020~2015

Nov 19, 2021

SyneuRx Announces Oral COVID-19 Twindemic Antiviral Drug Candidate Pentarlandir Has Entered Final Portion of FDA Phase II Testing

Jun 23, 2021

SyneuRx Announces Closing of Public Offering

Jun 08, 2021

Taiwan FDA Approves SyneuRx’s IND Application for COVID-19 Clinical Trial

Jun 03, 2021

SyneuRx Files an IND Application for COVID-19 Clinical Trial in Taiwan SyneuRx Initiates Clinical Trial SNB01 Pentarlandir® For Covid-19

Apr 27, 2021

SyneuRx Initiates Clinical Trial SNB01 Pentarlandir® For Covid-19

Mar 26, 2021

US FDA Approves SyneuRx’s IND Application for a Phase II Clinical Trial for Adult Patients with Treatment-Resistant Depression and Suicidal Symptoms

Mar 08, 2021

TFDA Approves SyneuRx's Schizophrenia Trials in Taiwan as part of its Global Schizophrenia Trials

Feb 26, 2021

Ω-NaBen, the Ultimate and Supreme Sodium Benzoate

Feb 04, 2021

US FDA Approves SyneuRx’s IND Application for a First-in-Human, Proof of Principle Clinical Trial for Patients with Early and Mild COVID-19